SAN Sanofi

Online availability of Sanofi’s half-year financial report for 2021

Online availability of Sanofi’s half-year financial report for 2021

Online availability of Sanofi’s half-year financial report for 2021



PARIS – July 29, 2021 - Sanofi announces that its half-year financial report for the period ending June 30, 2021 is now available and has been filed with the French market regulator Autorité des marchés financiers (AMF) and submitted to the U.S. Securities and Exchange Commission (SEC) under form 6-K.

This document may be found on the company’s corporate website: and downloaded from the “Investors” page, under the heading “Regulated Information in France”.

About Sanofi 

Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions. 

With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe. 

Media Relations Contacts  

Ashleigh Koss

Tel: +1 (908) 205-2572

Sandrine Guendoul

Tel.: +33 (0)6 25 09 14 25

Nicolas Kressmann

Tel.: +1 (732) 532-5318

Investor Relations Contacts Paris 

Eva Schaefer-Jansen 

Arnaud Delepine 

Nathalie Pham 

Investor Relations Contacts North America 

Felix Lauscher 

Fara Berkowitz 

Suzanne Greco  

Tel.: +33 (0)1 53 77 45 45  

 

 

Attachment



EN
29/07/2021

Underlying

SANSanofi

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sanofi

 PRESS RELEASE
Free
SAN SANOFI

Press Release: Filing of an amendment to the French “Document d’Enregi...

Press Release: Filing of an amendment to the French “Document d’Enregistrement Universel” containing the Annual Financial Report Filing of an amendment to the French “Document d’Enregistrement Universel” containing the Annual Financial Report Paris, March 4, 2026. Sanofi announces today the filing of an amendment to its “Document d’Enregistrement Universel” containing its Annual Financial Report with the French market regulator Autorité des marchés financiers (AMF). This amendment notably includes additions to the report on corporate governance established in accordance with French law. ...

6h / 27m 1 EN
 PRESS RELEASE
Free
SAN SANOFI

Communiqué de presse : Dépôt d’un amendement au Document d’Enregistrem...

Communiqué de presse : Dépôt d’un amendement au Document d’Enregistrement Universel 2025, contenant le Rapport Financier Annuel Dépôt d’un amendement au Document d’Enregistrement Universel 2025, contenant le Rapport Financier Annuel Paris, le 4 mars 2026. Sanofi annonce avoir déposé ce jour un amendement à son Document d’Enregistrement Universel 2025 contenant le Rapport Financier Annuel auprès de l’Autorité des marchés financiers (AMF) en France. Cet amendement intègre notamment des compléments au (i) rapport de gestion et au (ii) rapport sur le gouvernement d’entreprise. Le document pe...

6h / 27m 1 EN
 PRESS RELEASE
Free
SAN SANOFI

Press Release: Sanofi’s rilzabrutinib earns orphan drug designation in...

Press Release: Sanofi’s rilzabrutinib earns orphan drug designation in Japan for IgG4-related disease Sanofi’s rilzabrutinib earns orphan drug designation in Japan for IgG4-related disease Designation based on positive data from a phase 2 study of rilzabrutinib in IgG4-RDThird global orphan drug designation for rilzabrutinib in IgG4-RD, underpinning Sanofi’s commitment to rare immune-mediated diseases Paris, March 2, 2026 – The Ministry of Health, Labour and Welfare (MHLW) in Japan has granted orphan drug designation to rilzabrutinib, a novel, oral, reversible covalent Bruton’s tyrosine ...

March 2, 2026 1 EN
 PRESS RELEASE
Free
SAN SANOFI

Communiqué de presse : Le rilzabrutinib de Sanofi obtient la désignati...

Communiqué de presse : Le rilzabrutinib de Sanofi obtient la désignation de médicament orphelin au Japon pour la maladie liée aux IgG4 Le rilzabrutinib de Sanofi obtient la désignation de médicament orphelin au Japon pour la maladie liée aux IgG4 La désignation s’appuie sur les données positives d’une étude de phase 2 sur le rilzabrutinib dans la maladie liée aux IgG4Il s’agit de la troisième désignation mondiale de médicament orphelin pour le rilzabrutinib dans le traitement de la maladie liée aux IgG4, soulignant l’engagement de Sanofi dans la lutte contre les maladies rares à médiation...

March 2, 2026 1 EN
 PRESS RELEASE
Free
SAN SANOFI

Press Release: Sanofi and Regeneron’s Dupixent recommended for EU appr...

Press Release: Sanofi and Regeneron’s Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment Sanofi and Regeneron’s Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment If approved, Dupixent would be the first targeted medicine in the EU indicated for children aged two to 11 years with CSU inadequately controlled by standard-of-care antihistamine treatment CSU is a chronic skin disease with underlying type 2 inflammation that can c...

February 27, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch